多西紫杉醇联合顺铂与紫杉醇联合顺铂治疗晚期非小细胞肺癌的临床随机对照研究

A randomized study of docetaxel plus cisplatin verse paclitaxel pins cisplatin in untreated advanced non - small cell lung cancer

目的比较多西紫杉醇联合顺铂（DC）方案与紫杉醇联合顺铂（PC）方案治疗晚期非小细胞肺癌的疗效、毒副作用及生存情况。方法经病理学确诊的82例晚期非小细胞肺癌患者随机分为DC组和PC组。DC组：多西紫杉醇75mg／m^2，静脉滴注，第1天；顺铂75mg/m^2，分成3天静脉滴注，第2—4天。PC组：紫杉醇150mg／m^2，静脉滴注，第1天；顺铂75mg／m^2，分成3天静脉滴注，第2～4天。两种方案均以21d为一周期。两个周期以上化疗的患者评价疗效、毒副作用并分析生存情况。结果两组的总有效率、中位生存期、中位疾病进展时间以及1年和2年生存率差异无统计学意义（P〉0．05）。两组的Ⅲ度及Ⅳ度不良反应差异无统计学意义（P〉0．05）。结论针对晚期非小细胞肺癌的化疗，多西紫杉醇联合顺铂方案与紫杉醇联合顺铂方案相比较，疗效相当，生存期接近，毒副作用小，耐受性好，均为化疗方案的一线选择。

Objective To compare docetaxel plus cisplatin（DC） versus paclitaxel plus cisplatin （PC） for patients with advanced non - small cell lung cancer. Methods Eighty - two patients with advanced non - small cell lung cancer were randomly assigned to reive either DC or PC. Patients received docetaxel 75 mg/m^2 on day 1 and cisplatin 75 mg/m^2 divided into doses on days 2 to 4 in DC group and paclitaxel 150 mg/m^2 on day 1 and cisplatin 75 mg/m^2 divided into doses on days 2 to 4 in PC group. The cycle of two regimens was repeated every 3 weeks. Response and toxicity were evaluated in patients who completed two cycles of chemotherapy at least. Rusults There was no significant difference in response rate, median survival rate, median time to tumor progression or survival rate between two groups （P 〉 0.05 ） . There was no significant difference in grade m and Ⅳ toxieities between two groups （ P 〉 0.05 ）. Conclusions Among the chemotherapy methods to advanced non - small cell lung cancer, DC has similar response rate and survivals with PC, and its toxicity is well - tolarated. Both of these methods are effective first- line treatment to non- small cell lung cancer.